This inventor holds 2 USPTO granted patents. Top assignee: Wakamoto Pharmaceutical Co., Ltd.. Active years: 1991-1993.
Location History:
- Morinosato, JP (1991)
- Atsugi, JP (1993)
Company Filing History:
Years Active: 1991-1993
Title: Manami Umezawa: Innovator in Aldose Reductase Inhibition
Introduction
Manami Umezawa is a prominent inventor based in Morinosato, Japan. She has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that inhibit aldose reductase, an enzyme linked to diabetic complications. With a total of 2 patents, her work is paving the way for innovative treatments in diabetes care.
Latest Patents
Umezawa's latest patents include the development of tetrazoleacetic acid derivatives that exhibit excellent aldose reductase inhibitory activity. One of her notable inventions is a tetrazoleacetic acid derivative represented by a specific general formula, which shows promise as an essential component of preventive medicine and remedies for diabetic complications. Another patent focuses on a similar derivative, which has low toxicity and is effective in treating diabetic complications.
Career Highlights
Manami Umezawa is currently associated with Wakamoto Pharmaceutical Co., Ltd., where she continues her research and development efforts. Her innovative work has garnered attention in the pharmaceutical industry, contributing to advancements in diabetes treatment.
Collaborations
Umezawa collaborates with esteemed colleagues such as Sinji Inukai and Yoshihiro Horio, enhancing the research environment and fostering innovation in her field.
Conclusion
Manami Umezawa's contributions to the field of medicinal chemistry, particularly in aldose reductase inhibition, highlight her role as a key innovator in diabetes treatment. Her ongoing research promises to lead to significant advancements in preventive medicine.